OlainFarm
  • Русский
  • Latviešu
  • English
  • About Company
    • Olainfarm
      • Strategy
      • Our commitment
      • Olainfarm worldwide
      • Virtual tour
      • Awards
      • Virtual tour
      • History
      • In memoriam
    • Olainfarm Group
    • Management
      • Supervisory Council
      • Management Board
    • Quality
      • Licences and Certificates
      • Quality policy
    • Sustainability
      • Corporate Governance
      • Environment
      • Corporate Social Responsibility
    • Participation in Projects
      • Pharmaceutical, Biomedical and Medical Technology Competence Center
      • Work-based learning and internships
      • Innovation voucher
      • Reduction of greenhouse gas emissions by reconstruction of cold station and its engineering system
  • Products and Services
    • Products
    • APIs and Intermediates
    • Services
      • Contract Manufacturing
      • Quality Control and Assurance
      • Co-Development
    • Pharmacovigilance
    • Your health
  • Research and Development
    • R&D of APIs and Intermediates
    • R&D of Final Dosage Forms
    • Preclinical Trials
    • Clinical Trials
  • For investors
    • Share buy-back
    • Corporate Governance
      • Governance
      • Shareholders
      • Supervisory Council
      • Management Board
      • Committees of the Supervisory Council
      • Management reports and documents
    • Shares
      • Dividends
    • Financial results
      • Financial Calendar
      • Webinars
      • Future outlook
      • Analysts
    • ESG reports
    • Stock exchange announcments
    • Privacy notice of shareholders’ data processing
    • Contacts for investors
  • Careers
    • Vacancies
    • Career Contacts
    • Application Form
    • Internship
    • Personnel Policy
    • Privacy Disclaimer
  • Contacts
  • Media
    • News
    • Photo Library
    • Media Contacts
Training courses
English
  • Русский
  • Latviešu
  • English
Training courses
  • Substances
Drug substances (APIs)
Intermediates
Adamantane derivatives Quinuclidine derivatives

Olainfarm

  • Olainfarm
  • Strategy
  • Management
  • Olainfarm worldwide
  • Corporate Governance
  • History

Products & Services

  • Over the Counter (OTC)
  • Prescription medicines
  • APIs and Intermediates
  • Pharmacovigilance
  • Services

Research & Development

  • R&D of APIs and Intermediates
  • R&D of Final Dosage Forms
  • Preclinical Trials
  • Clinical Trials
  • Cooperation

Investors

  • Corporate Governance
  • Stock exchange announcments
  • Shareholders’ Meetings
  • Contacts for investors
  • Financial Calendar
  • Webinars
© 2023 OlainFarm
  • Privacy Notice
  • |Renew/change cookie consent
  • |Cookie usage policy
  • FB
  • Tw
  • Youtube
    • ru
    • lv
    • en

OlainFarm news

HEALTHCARE SPECIALIST, please apply for Olainfarm news!

Name:
Surname:
Speciality:
E-mail address:
Phone number:
* These are MANDATORY data
** Mobile phone number or email address required

By entering your personal data and clicking "AGREE", m Company Olainfarm (hereafter - Olainfarm) is entitled to use your personal data, to inform you about Olainfarm products and events for healthcare professionals.
You have the right to withdraw this consent at any time in the manner specified in the Olainfarm information message or, by writing to an email address: dataprotection@olainfarm.com.
Manager: Olainfarm. Contact information for personal data protection issues: 5 Rupnicu Street, Olaine, LV-2114, Latvia dataprotection@olainfarm.com, +371 28327856.
Additional information on personal data processing is available HERE.